Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · IEX Real-Time Price · USD
7.54
-0.60 (-7.37%)
At close: Jul 2, 2024, 4:00 PM
7.56
+0.02 (0.27%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
5.29B USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
Dec 31, 2020 | 860.00K | - | - |
Dec 31, 2019 | - | - | - |
Jan 31, 2019 | 57.09M | 41.64M | 269.50% |
Jan 31, 2018 | 15.45M | 12.57M | 436.46% |
Jan 31, 2017 | 2.88M | - | - |
Jan 31, 2016 | 0 | - | - |
Jan 31, 2015 | 0 | - | - |
Jan 31, 2014 | 0 | - | - |
Jan 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organon & Co. | 6.35B |
DENTSPLY SIRONA | 3.94B |
R1 RCM | 2.31B |
Lantheus Holdings | 1.37B |
Tempus AI | 562.02M |
Doximity | 475.42M |
Glaukos | 326.43M |
Krystal Biotech | 95.95M |
SMMT News
- 5 days ago - Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors - Business Wire
- 4 weeks ago - Summit Therapeutics stock rallies as institutional buyer loads up on shares - Invezz
- 4 weeks ago - Summit Raises $200 Million; Also Expands License Territories for Ivonescimab - Business Wire
- 4 weeks ago - Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA - Business Wire
- 4 weeks ago - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy - Business Wire
- 4 weeks ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster - Market Watch
- 4 weeks ago - Summit Therapeutics cancer therapy succeeds in late-stage China study - Reuters